Agile Therapeutics (Agile Therapeutics) Gross Profit : $12.84 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Agile Therapeutics Gross Profit?

Agile Therapeutics's gross profit for the three months ended in Mar. 2024 was $4.04 Mil. Agile Therapeutics's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $12.84 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Agile Therapeutics's gross profit for the three months ended in Mar. 2024 was $4.04 Mil. Agile Therapeutics's Revenue for the three months ended in Mar. 2024 was $5.72 Mil. Therefore, Agile Therapeutics's Gross Margin % for the quarter that ended in Mar. 2024 was 70.61%.

Agile Therapeutics had a gross margin of 70.61% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of Agile Therapeutics was 62.35%. The lowest was -161.35%. And the median was 45.69%.

Agile Therapeutics Gross Profit Historical Data

The historical data trend for Agile Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics Gross Profit Chart

Agile Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

0.47

-6.62

4.05

10.62

Agile Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Profit	Get a 7-Day Free Trial															1.81	3.20	4.19	1.42	4.04

Competitive Comparison of Agile Therapeutics's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agile Therapeutics's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Agile Therapeutics's Gross Profit falls into.

Agile Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Agile Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	19.593	-	8.978
	=	10.62

Agile Therapeutics's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )	=	Revenue	-	Cost of Goods Sold
	=	5.716	-	1.68
	=	4.04

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.84 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Agile Therapeutics's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	4.04	/	5.716
	=	70.61 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Agile Therapeutics (OTCPK:AGRX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Agile Therapeutics had a gross margin of 70.61% for the quarter that ended in Mar. 2024 => Durable competitive advantage

Agile Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Agile Therapeutics (Agile Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 College Road East, Suite 310, Princeton, NJ, USA, 08540

Website

https://www.agiletherapeutics.com

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.

Executives

Scott M Coiante	officer: Chief Financial Officer	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Josephine Torrente	director	101 POOR FARM ROAD, PRINCETON NY 08540
Sandra Carson	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
John W Hubbard	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Amy Welsh	officer: Chief Commercial Officer	500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540
Alfred Altomari	director, officer: Chief Executive Officer	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Dennis Reilly	officer: Chief Financial Officer	600 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jason Butch	officer: Principal Accounting Officer	101 POOR FARM ROAD, PRINCETON NJ 08540
Paul Korner	officer: Sr. VP & Chief Medical Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abhijeet J Lele	director, See remarks	C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003